Use of Imaging Modalities in Real Life: Impact on Visual Acuity Outcomes of Ranibizumab Treatment for Neovascular Age-Related Macular Degeneration in Germany.
Joachim WachtlinGeorg SpitalSteffen Schmitz-ValckenbergSandra LiakopoulosJessica VögelerBettina MüllerManuela Schmidtnull Ocean Study GroupPublished in: Journal of ophthalmology (2020)
Low number of visits as well as high number of treatment decisions without the use of OCT may contribute to undertreatment and poorer functional outcomes in patients undergoing ranibizumab treatment for nAMD in Germany. One potential reason for this could be that OCT was not covered by insurance for all patients during the study.
Keyphrases
- age related macular degeneration
- patients undergoing
- diabetic retinopathy
- end stage renal disease
- high resolution
- healthcare
- type diabetes
- chronic kidney disease
- newly diagnosed
- prognostic factors
- ejection fraction
- combination therapy
- peritoneal dialysis
- endothelial cells
- skeletal muscle
- health insurance
- photodynamic therapy
- weight loss